Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy—A Follow-Up Study of First Experiences

Pathology and Oncology Research

Volumn 20, Issue 4, 2014, Pages 939-944

  Kovács, Péter ^a,b   Pánczél, Gitta ^a   Borbola, Kinga ^a   Juhász, Gabriella ^b   Liszkay, Gabriella ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anxiety; Depression; Interferon; Ipilimumab; Malignant melanoma

Indexed keywords

ALPHA INTERFERON; IMMUNOLOGIC FACTOR; IPILIMUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; CHEMICALLY INDUCED; COMPLICATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MELANOMA; MENTAL DISEASE; MIDDLE AGED; PROGNOSIS; PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MELANOMA; MENTAL DISORDERS; MIDDLE AGED; PROGNOSIS; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 84936081471     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9777-7     Document Type: Review

References (40)

1. Petrella T, Verma S, Spithoff K, McCready D (2012) Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol 26(4):413–423
2. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(85):1–7
3. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501
4. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27(1):3–9
5. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012
6. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9:587–595
7. Rusthoven JJ, Quirt IC, Iscoe NA et al (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14:2083–2090
8. Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166
9. Verma S, Quirt I, McCready D, Bak K, Charrette M, Iscoe N (2006) Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106:1431–1442
10. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526
11. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
12. Garbe C, Peris K, Hauschild A et al (2012) Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–update. Eur J Cancer 48:2375–2390
13. Wheatley K, Ives N, Eggermont A, on behalf of International Malignant Melanoma Collaborative Group et al (2007) Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 25(suppl 18):8526
14. Friebe A, Horn M, Schmidt F et al (2010) Dose-dependent development of depressive symptoms during adjuvant interferon treatment of patients with malignant melanoma. Psychosomatics 51:466–473
15. Bonaccorso S, Marino V, Biondi M et al (2002) Depression induced by treatment with interferon- in patients affected by hepatitis C virus. J Affect Disord 72:237–241
16. Borden EC, Parkinson D (1998) A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol 25:3–8
17. Dieperink E, Willenbring M, Ho SB (2000) Neuropsychiatric symptoms associated with hepatitis C and interferon: a review. Am J Psychiatry 157:867–876
18. Dafny N, Prieto-Gomez B, Reyes-Vazquez C (1985) Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity. J Neuroimmunol 9:1–12
19. Schaefer M, Engelbrecht MA, Gut O et al (2002) Interferon (IFN) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry 26:731–746
20. Zung WWK (1965) A self-rating depression scale. Arch Gen Psychiatry 12:63–70
21. Simon A (1994) A Zung-féle Önértékelő Depresszió Skála. In: Mérei F, Szakács F (eds) Pszichodiagnosztikai Vademecum. Nemzeti Tankönyvkiadó, Budapest, pp 180–185
22. Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologists Press, Palo Alto
23. Sipos K, Sipos M (1983) The development and validation of the Hungarian form of the STAI. In: Spielberger CD, DiazGuerro R (eds) Cross cultural anxiety, 2. Hemisphere Publishing Corporation, Washington-London, pp 51–61
24. Caldwell RA, Pearson JL, Chin RJ (1987) Stress-moderating effects: social support in the context of gender and locus of control. Personal Soc Psychol Bull 13(1):5–17
25. Rychetnick L, McCaffery K, Morton R, Irwing L (2012) Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. Psychooncology 22(4):721–736
26. Kasparian AN, Sansom-Daly U, McDonald RP, Meiser B, Butow PN, Mann GJ (2012) The nature and structure of psychological distress in people at high risk for melanoma: a factor analytic study. Psychooncology 21:845–856
27. Meyer F, Ehrlich M, Peteet J (2009) Psycho-oncology: a review for the general psychiatrist. FOCUS 7:317–331
28. Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients. Cancer 115:5349–5361
29. Fawzy IF, Fawzy NW, Hyun CS et al (1993) Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50:681–689
30. Eggermont AM, Suciu S, Santinami M, EORTC Melanoma Group et al (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 372(9633):117–126
31. Trask P, Paterson A, Esper P et al (2004) Longitudinal course of depression, fatigue, and quality of life in patients with high-risk melanoma receiving adjuvant interferon. Psychooncology 13:526–536
32. Eggermont AMM, Suciu S, MacKie R, for the EORTC Melanoma Group et al (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366:1189–1196
33. Grob JJ, Dreno B, de la Salmoniere P et al (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. Lancet 351:1905–1910
34. Müller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988–1000
35. Licinio J, Kling MA, Hauser P (1998) Cytokines and brain function: relevance to interferon-alpha induced mood and cognitive changes. Semin Oncol 25(suppl 1):S30–S38
36. Reiche EMV, Nunes SOV, Morimoto HK (2004) Stress, depression, the immune system and cancer. Lancet 5:617–625
37. Musselmann DL, Lawson DH, Gumnick JF et al (2001) Paroxetine for the prevention of depression induced by highdose interferon alpha. N Engl J Med 344:961–966
38. Almeida AG, Guindalini C, Batista-Neves S et al (2010) Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry 32:401–405
39. Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trends Immunol 27:24–31
40. Heinze S, Egberts F, Rötzer S et al (2010) Depressive mood changes and psychiatric symptoms. J Immunother 33:106–114